September 15th 2025
A study found 16S nanopore sequencing offers high accuracy in identifying intraamniotic infection, a major contributor to preterm delivery.
CDC recommends Pfizer’s maternal RSV vaccine to protect newborns
September 26th 2023Ahead of the first fall and winter virus seasons in which vaccines are available for COVID-19, influenza, and respiratory syncytial virus (RSV), the Centers for Disease Control and Prevention is recommending Pfizer’s maternal vaccine to protect newborns from severe RSV illness.
Read More
Pitocin in late stage labor for reduction of obstetrical hemorrhage
September 13th 2023Study authors from a poster highlighted at the 2023 Society of OB/GYN Hospitalists Annual Clinical Meeting suggest that implementing a standardized oxytocin infusion protocol may increase patient safety, while simultaneously reducing the rate of postpartum hemorrhage.
Read More
Implementing advanced fetal heart rate monitoring interpretation into your practice
September 12th 2023Sean Esplin, MD, maternal-fetal medicine physician, senior medical director for women’s health, professor, Department of OB/GYN, University of Utah, discusses his presentation on advanced fetal heart rate monitoring interpretation at the 2023 Society of OB/GYN Hospitalists Annual Clinical Meeting in Chicago, Illinois.
Watch
Recognizing the importance of aesthetics in cesarean section closures
September 12th 2023In a poster featured at the 2023 Society for OB/GYN Hospitalists Annual Clinical Meeting, study investigators underline the importance of aesthetics in cesarean section closures as both providers and patients.
Read More
Model developed for predicting postpartum hemorrhage
August 28th 2023In a recent study, the most effective model for predicting postpartum hemorrhage in patients with pernicious placenta previa used a logical least absolute shrinkage and selection operator adopting risk factors of ultrasound and magnetic resonance imaging.
Read More
FDA approves Pfizer’s maternal vaccine to prevent RSV in infants
August 22nd 2023Approved for use at 32 weeks through 36 weeks gestation, Pfizer’s maternal respiratory syncytial vaccine (Abrysvo), is delivered through a single dose injection to the muscle, and is the first vaccine for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD because of RSV in infants (birth to 6 months).
Read More